Clinical Trial

A Single-arm, Phase II Clinical Trial of ASPIRin to prEvent Venous Thromboembolism in Patients With Advanced Germ Cell Tumors Receiving Chemotherapy

Study acronym: ASPIRE
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to the 6-month Venous Thromboembolism (VTE)-free rate in participants with advanced germ cell cancer at high risk of VTE who are receiving standard of care cisplatin-based chemotherapy and low-dose acetylsalicylic acid (ASA) and compare to relevant historical controls
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-03-04; most recent amendment 2026-07-22.
Status change: Not Yet Recruiting → Recruiting 2025-07-21
Trial Details
NCT Number NCT06866964
Lead Sponsor Wake Forest University Health Sciences
Collaborators: Atrium Health Wake Forest Baptist
Conditions Germ Cell Tumor, Testicular Cancer
Enrollment 35 participants
Start Date 2025-08-28
Primary Completion 2029-08 (estimated)
Study Completion 2031-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24